Symptomatic primary human immunodeficiency virus infection;Primo-infection symptomatique par le virus de l'immunodeficience humaine

Revue de Medecine Interne

Volumn 18, Issue 1, 1997, Pages 37-46

  Bachmeyer, C ^a   Grateau, G ^b   Sereni, D ^b  

^a CENTRE HOSPITALIER LAENNEC   (France)

^b Hôpital Cochin ^*  (France)

Author keywords

HIV; primary infection; prognostic value; seroconversion

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; ANTIVIRUS AGENT; VIRUS ANTIBODY; VIRUS ANTIGEN;

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MENINGITIS; PATHOGENESIS; PROGNOSIS; REVIEW; RISK FACTOR; SEROCONVERSION; IMMUNOLOGY; PATHOPHYSIOLOGY;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; HIV INFECTIONS; HUMANS; PROGNOSIS;

EID: 0031035103     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(97)84392-5     Document Type: Article

References (95)

1. 1 Anonymous. Needlestick transmission of HTLV-III from a patient infected in Africa. Lancet 1984;ii:1376-7
2. 2 Cooper DA, Gold J, MacLean P et al. Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet 1985;i:537-40
3. 3 Centers for Disease Control. Classification system for human T lymphotropic virus type III/lymphadenopathy associated virus infections. MMWR 1986;35:334-9
4. 4 Lange JMA, Parry JV, De Wolf F, Mortimer PP, Goudsmit J. Diagnostic value of specific IgM antibodies in primary HIV infection. Br Med J 1986;293:1459-62
5. 5 Fox R, Eldred LJ, Fuchs EJ et al. Clinical manifestations of acute infection with human immunodeficiency virus in a cohort of gay men. AIDS 1987;1:35-8
6. 6 Pedersen C, Lindhardt BO, Jensen BL et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. Br Med J 1989;299:154-7
7. 7 Gaines H, von Sydow M, Pehrson PO, Lundbergh P. Clinical picture of primary HIV infection presenting as a glandular fever-like illness. Br Med J 1988;297:1363-8
8. 8 Weber JN, Wadsworth J, Rogers LA et al. Three-year prospective study of HTLVIII/LAV infection in homosexual men. Lancet 1986;i:1179-82
9. 9 Boyko WJ, Schechter MT, Craib KJP et al. The Vancouver lymphadenopathy-AIDS study. 7. Clinical and laboratory features of 87 cases of primary HIV infection. Can Med Assoc J 1987;137:109-13
10. 10 Dorrucci M, Rezza G, Vlahov D et al. Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. AIDS 1995;9:597-604
11. 11 Niu MT, Stein DS, Schnittman SM. Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infection. J Infect Dis 1993;168:1490-501
12. 12 Quarto M, Germinario C, Fontana A, Barbutis S. HIV transmission through kidney transplantation from a living related donnor. N Engl J Med 1989;320:1754
13. 13 de Noray G, Biron F, Verrier B et al. Manifestations cliniques et biologiques de la primo-infection par le virus de l'immunodéficience humaine : revue de la littérature. Méd Mal Infect 1993;23:643-52
14. 14 Tindall B, Barker S, Donovan B et al. Characterization of the acute clinical illness associated with human immunodeficiency virus infection. Arch Intern Med 1988;148:945-9.
15. 15 Sinicco A, Palestro G, Caramello B et al. Acute HIV-I infection: clinical and biological study of 12 patients. J Acquired Immune Defic Syndrome 1990;3:260-5
16. 16 Ho DD, Sarngadharan MG, Resnick I, Dimarzo-Veronese R, Rota TR, Hirsch MS. Primary human T-lymphotropic virus type III infection. Ann Intern Med 1985;103:880-3
17. 17 Kessler HA, Blaauw B, Spear J, Falk LA, Paul DA, Landay A. Diagnosis of human immunodeficiency virus infection in seronegative homosexuals presenting with an acute viral syndrome. JAMA 1987;258:1196-9
18. 18 Mortier E, Zahar JR, Gros I et al. Primary infection with human immunodeficiency virus that presented as Stevens-Johnson syndrome. Cl Infect Dis 1994;19:798
19. 19 Rabeneck L, Popovic M, Gartner S et al. Acute HIV infection presenting with painful swallowing and esophageal ulcers. JAMA 1990;263:2318-22
20. 20 Boufassa F, Bachmeyer C, Carré N et al. Influence of neurologic manifestations of primary human immunodeficiency virus infection on disease progression. J Infect Dis 1995;171:1190-5
21. 21 Carne CA, Tedder RS, Smith A et al. Acute encephalopathy coincident with seroconversion for anti-HTLV-III. Lancet 1985;ii:1206-8
22. 22 Ho DD, Rota TR, Schooley RT et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patient with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med 1985;313:1493-7
23. 23 Denning DW, Anderson J, Rudge P et al. Acute myelopathy associated with primary infection with human immunodeficiency virus. Br Med J 1987;294:143-4
24. 24 Piette AM, Tusseau F, Vignet alon D et al. Acute neuropathy coincident with seroconversion for anti-LAV/HTLV-III. Lancet 1986;i:852
25. 25 Brew BJ, Perdices M, Darveniza P et al. The neurological features of early and 'latent' human immunodeficiency virus infection. Aust NZ J Med 1989;19:700-5
26. 26 Wiselka MJ, Nicholson KG, Ward SC, Flower AJE. Acute infection with human immunodeficiency virus associated with facial nerve palsy and neuralgia. J infect 1987;15:189-94
27. 27 Hagberg L, Malmvall BE, Svennerholm L, Alestig K, Norkrans G. Guillain-Barré syndrome as an early manifestation of HIV central nervous system infection. Scand J Infect Dis 1986;18:591-2
28. 28 Tindall B, Hing M, Edwards P, Barnes T, MacKie A, Cooper DA. Severe clinical manifestations of primary HIV infection. AIDS 1989;3:747-9
29. 29 Longworth DL, Spech TJ, Ahmad M et al. Lymphocytic alveolitis in primary HIV infection. Cleve Clin J Med 1990;57:379-82
30. 30 del Rio C, Soffer O, Widell JL, Judd RL, Slade BA. Acute human immunodeficiency virus infection temporally associated with rhabdomyolysis, acute renal failure, and nephrosis. Rev Infect Dis 1990;12:282-5
31. 31 Pena JM, Martinez-Lopez MA, Arnalich F, Barbado FJ, Vazquez JJ. Esophageal candidiasis associated with acute infection due to human immunodeficiency virus: case report and review. Rev Infect Dis 1991;13:872-5
32. 32 Moss PJ, Read RC, Kudesia G, McKendrick MW. Prolonged cryptosporidiosis during primary HIV infection. J Infect 1995;30:51-3
33. 33 Gupta KK. Acute immunosuppression with HIV seroconversion. N Engl J Med 1993;328:288-9
34. 34 Cooper DA, Tindall B, Wilson E, Imrie AA, Penny R. Characterization of T-lymphocyte responses during primary HIV infection. J Infect Dis 1988;157:889-96
35. 35 Ribera E, Ocana I, Almirante B, Gomez J, Monreal P, Martonez-Vasquez JM. Autoimmune neutropenia and thrombocytopenia associated with development of antibodies to human immunodeficiency virus. J Infect 1989;18:167-70
36. 36 PM Girard, Matheron S, Oksenhendler E et al. Hépatite aiguë au cours de primo-infections par VIH. Gastroentérol Clin Biol 1987;11:803-4
37. 37 McMillan A, Bishop PE, Aw D, Peutherer JF. Immunohistology of the skin rash associated with acute HIV infection. AIDS 1989;3:309-12
38. 38 Balslev E, Thomsen HK, Weismann K. Histopathology of acute human immunodeficiency virus exanthema. J Clin Pathol 1990;43:201-2
39. 39 Sonnerborg AB, von Stedingk LV, Hansson LO, Strannegard OO. Elevated neopterin and beta2-microglobulin levels in blood and cerebrospinal fuid early in HIV-1 infection. AIDS 1989;3:277-83
40. 40 Fox CH, Tenner-Racz K, Racz P, Firpo A, Pizzo PA, Fauci AS. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis 1991 164:1051-7
41. 41 Pantaleo G, Graziosi C, Demarest JF et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8
42. 42 Embretson J, Zupancic M, Ribas JL et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-62
43. 43 Goudsmit J, de Wolf F, Paul DA et al. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet 1986;ii:177-80
44. 44 von Sydow M, Gaines H, Sönnerborg A, Forsgren M, Pehrson PO, Strannegard O. Antigen detection in primary HIV infection. Br Med J 1988;296:238-40
45. 45 Brun-Vesinet F, Dormont J. Mesure de la charge virale dans le suivi des patients atteints par le VIH. Méthodes et indications. Paris : Flammarion Médecine-Sciences, 1996
46. 46 Rututu P, Suni J, Oksanen K, Rututu T. Primary infection with HIV in a severely immunosuppressed patient with acute leukemia. Scand J Infect Dis 1987;19:369-72
47. 47 Centers for Disease Control. Transfusion associated human T-lymphotropic virus type III/Lymphadenopathy-associated virus infection from a seronegative donnor - Colorado. Morb Mortal Wkly Rep 1986;35:389-91
48. 48 Lepage P, Van de Perre P, Carael M et al. Postnatal transmission of HIV from mother to child. Lancet 1987;ii:400
49. 49 Colebunders R, Kapita B, Nekwei W et al. Breastfeeding and transmission of HIV. Lancet 1988;ii:1487
50. 50 Healey DS, Maskill WJ, Gust ID. Detection of anti-HIV IgM by particle agglutination following acute HIV infection. AIDS 1989;3:301-4
51. 51 Cooper DA, Imrie AA, Penny R. Antibody response to human immunodeficiency virus after primary infection. J Infect Dis 1987;155:1113-8
52. 52 Gaines, von Sydow M, Sonnerborg A et al. Antibody response in primary human immunodeficiency virus infection. Lancet 1987;i:1249-53
53. 53 Petersen LR, Satten GA, Dodd R et al. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. Transfusion 1994;4:283-9
54. 54 Zaaijer HL, Exel-Oehlers PV, Kraaijeveld T, Altena E, Lelie PN. Early detection of antibodies to HIV-1 by third-generation assays. Lancet 1992;340:770-2
55. 55 Tsang ML, Evans LA, McQueen P et al. Neutralising antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion. J Infect Dis 1994;170:1141-7
56. 56 Zwart G, Back NK, Ramautarsing C, Valk M, Van der Hoek L. Frequent and early HIV-MN neutralizing capacity in sera from Dutch HIV-1 seroconverters in related to antibody reactivity to peptides from the gp 120 V3 domain. AIDS Res Hum Retroviruses 1994;10:245-51
57. 57 Pellegrin I, Legrand E, Neau D et al. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J Acquired Immune Defic Syndr 1996;11:438-47
58. 58 Mackewicz CE, Yang LC, Lifson JD, Levy JA. Non-cytolytic CD8 T-cell anti-HIV responses in primary HIV-1 infection. Lancet 1994;344:1671-3
59. 59 Mackewicz CE, Levy JA. CD8+ cell anti-HIV activity: nonlytic suppression of virus replication. AIDS Res Hum Retroviruses 1992;8:629-40
60. 60 Zaunders J, Carr A, McNally L, Penny R, Cooper DA. Effects of primary HIV-1 infection on subsets of CD4+ and CD8+ T lymphocytes. AIDS 1995;9:561-6
61. 61 Pedersen C, Dickmeiss E, Gaub J et al. T-cell subset alterations and lymphocyte responsiveness to mitogens and antigen during severe primary infection with HIV: a case series of seven consecutive seroconverters. AIDS 1990;4:523-6
62. 62 Sinicco A, Biglino A, Sciandra M et al. Cytokine network and acute primary HIV-1 infection. AIDS 1993;7:1167-72
63. 63 Rappociolo G, Toso JF, Torpey DJ, Gupta P, Rinaldo CR. Association of alpha interferon production with natural killer cell lysis of U937 cells infected with human immunodeficiency virus. J Clin Microbiol 1989;27:41-8
64. 64 Tyring SK, Cauda R, Tumbarello M et al. Synthetic peptides corresponding to sequences in HIV envelope gp 41 and gp 120 enhance in vitro production of interleukin-1 and tumor necrosis factor but depressed production of interferon-alpha, interferon-gamma and interleukin-2. Virol Immunol 1991;4:33-42
65. 65 Ammar A, Cibert C, Bertoli AM, Tsilivakos V, Jasmin C, Georgoulias V. Biological and biochemical characterization of a factor produced spontaneously by adherent cells of human immunodeficiency virus-infected patients inhibiting interleukin-2 receptor alpha chain (Tac) expression on normal T cells. J Clin Invest 1991;87:2048-55
66. 66 Scott-Algara D, Vuillier F, Marescu M, de Saint Martin J, Dighiero G. Serum levels of IL-2, IL1, TNF-alpha, and soluble receptor to IL-2 in HIV-1-infected patients. AIDS Res Hum Retroviruses 1991;7:381-6
67. 67 Graziosi C, Pantaleo G, Gantt KR et al. Lack of evidence for the dichotomy of Th 1 and Th 2 predominance in HIV-infected individuals. Science 1994;265:248
68. 68 Sinicco A, Fora R, Sciandra M, Lucchini A, Caramello P, Gioannini P. Risk of developing AIDS after primary acute HIV-1 infection. J Acquired Immune Defic Syndr 1993;6:575-81
69. 69 Keet IPM, Krijnen P, Koot M et al. Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS 1993;7:51-7
70. 6, AIDS, and death from AIDS? Br Med J 1994;309:1535-7
71. 71 Merrill JE, Koyanagi Y, Chen ISY. Interleukin 1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by HIV-1 binding to the CD4 receptor. J Virol 1989;63:4404-8
72. 72 Ward JW, Bush TJ, Perkins HA et al. The natural history of transfusion-associated infection with human immunodeficiency virus. Factors influencing the rate of progression to disease. N Engl J Med 1989;321:947-52
73. 73 Ringler DJ, Murphy GF, King NW. An erythematous maculopapular eruption in macaques infected with a HTLV-III-like virus (STLV-III). J Invest Dermatol 1986;87:674-7
74. 74 Clark SJ, Saag MS, Don Decker W et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324:954-60
75. 75 Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324:961-4
76. 76 Baumberger C, Kinloch-de-Loës S, Yerly S, Hirschel B, Perrin L. High level of circulating RNA in patients with symptomatic HIV-1 infection. AIDS 1993;7(suppl 2):S59-S64
77. 77 Henrard DR, Daar E, Farzadegan H et al. Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquired Immune Defic Syndr 1995;9:305-10
78. 78 Mellors JW, Kingsley LA, Rinaldo CR et al. Quantification of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9
79. 79 Nielsen C, Pedersen C, Lundgren JD, Gerstoft J. Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection. AIDS 1993;7:1035-40
80. 80 Roos MTL, Lange JMA, de Goede REY et al. Virus phenotype and immune response in primary human immunodeficiency virus type 1 (HIV-1) infection. J Infect Dis 1992;165:427-32
81. 81 Learmont J, Tindall B, Evans L et al. Long term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 1992;340:863-7
82. 82 Marechal V, Nicolas JC, Joab I, et al. Epstein-Barr virus transactivator antibodies in HIV infection. Lancet 1991;338:574
83. 83 Skolnik PR, Kosloff BR, Hirsch MS. Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus. J Infect Dis 1988;157:508-14
84. 84 Bonnetti A, Weber R, Vogt MW, Wunderli W, Siegenthaler W, Luthi R. Co-infection with human immunodeficiency virus-1 (HIV-1) and cytomegalovirus in two intravenous drug users. Ann Intern Med 1989;111:293-6
85. 85 Ragnaud JM, Tahbaz A, Buisson M et al. Primary coinfection with human immunodeficiency virus and cytomegalovirus presenting as acute rhabdomyolysis. Clin Infect Dis 1995;20:1077-8
86. 86 Kaslow RA, Duquesnoy R, Van Raden M et al. A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the Multicenter AIDS Cohort Study. Lancet 1990;335:927-30
87. 87 Louie LG, Newman B, King MC. Influence of host genotype on progression to AIDS among HIV-infected men. J Acquired Immune Defic Syndr 1991;4:814-8
88. 88 Ludlam CA, Tucker J, Steel CM et al. Human T-lymphotropic virus type III (HTLV III) infection in seronegative haemophiliacs after transfusion of factor VIII. Lancet 1985;ii:233-6
89. 89 Marion SA, Schechter MT, Weaver MS et al. Evidence that prior immune dysfunction predisposes to human immunodeficiency virus infection in homosexual men. J Acquired Immune Defic Syndr 1989;2:178-86
90. 90 Tindall B, Gaines H, Imrie A et al. Zidovudine in the management of primary HIV-1 infection. AIDS 1991;5:477-84
91. 91 Tindall B, Carr A, Goldstein D, Penny R, Cooper DA. Administration of zidovudine during primary HIV-1 infection may be associated with a less vigorous immune response. AIDS 1993;7:127-8
92. 92 Niu MT, Jermano JA, Reichelderfer P, Schnittman SM. Summary of the National Institutes of Health workshop on primary human immunodeficiency virus type-1 infection. AIDS Res Hum Retroviruses 1993;9:919-23
93. 93 Kinloch-de Loes S, Hirschel BJ, Hoen B et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995;333:408-13
94. 94 Perrin L, Yerli S, Lazzarin A et al. Reduced viremia and increased CD4/CD8 ratio in patients with primary HIV infection treated with AZT-DDI. In: XIth International Conference on AIDS, Vancouver, July 7-12, 1996:abstract B532
95. 95 Mayers DL, Yerly S, Perrin L et al. Prevalence of AZT-resistant (AZTR) HIV-1 in persons seroconverting in Switzermand, Australia, and the United States between 1988 and 1994 [Abstract]. In: 34th International Conference on Antimicrobial Agents and Chemotherapy, Orlando, Fla, October 4-7, 1994. Washington, DC: American Society for Microbiology, 1995: 29.